post transplant diabetes mellitus
TRANSCRIPT
![Page 1: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/1.jpg)
![Page 2: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/2.jpg)
Learning objectives• What is post transplant diabetes ?• How is it different from other types of diabetes ?• What are the challenges in prevention,diagnosis and management ?• Effect of transplant on glucose metabolism/diabetes• Effect of diabetes on transplant
![Page 3: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/3.jpg)
Terminology – no longer NODAT• 2003 – first international consensus guidelines on NODAT• 2013 – consensus guidelines revised
1. NODAT to PTDM2. Timing – PTDM to be diagnosed only after discharge, on stable
immunosuppression,without acute illness,rejection or infection3. HbA1c >6.5 % can be used to diagnose, but should not be used to screen for
PTDM , especially in the first year after transplantion
![Page 4: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/4.jpg)
![Page 5: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/5.jpg)
Incidence
Shivaswamy, Vijay; Boerner, Brian; Larsen, Jennifer (2015): Post-transplant diabetes mellitus: Causes, treatment, and impact on outcomes. In Endocrine reviews, pp. er20151084.
![Page 6: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/6.jpg)
Prevalence• 10 to 15% in literature *• 50 to 60% in JIPMER
Jenssen, Trond; Hartmann, Anders (2015): Emerging treatments for post-transplantation diabetes mellitus. In Nature reviews. Nephrology 11 (8), pp. 465–477.
![Page 7: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/7.jpg)
Risk factors
Sharif, Adnan; Cohney, Solomon (2015): Post-transplantation diabetes—state of the art. In The Lancet Diabetes & Endocrinology.
![Page 8: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/8.jpg)
Risk factors
Shivaswamy, Vijay; Boerner, Brian; Larsen, Jennifer (2015): Post-transplant diabetes mellitus: Causes, treatment, and impact on outcomes. In Endocrine reviews, pp. er20151084.
![Page 9: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/9.jpg)
Pathophysiology
![Page 10: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/10.jpg)
Immunosuppression and CV profile
![Page 11: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/11.jpg)
Role of stress/ inflammation• Ongoing graft vs host response• Acute vs chronic rejection• Reduced renal function• Greater incidence of chronic infections• HCV - ? Through hepatic inflammation• CMV
• Leucocyte mediated damage to β cells • Proinflammatory cytokines• Prophylaxis does not prevent PTDM
![Page 12: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/12.jpg)
Others• Vitamin D deficiency• RCT on vitamin D supplementation going on
• Statins• Class effect vs drug effect – atorvastatin > fluvastatin
![Page 13: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/13.jpg)
Diagnosis• Commonly used – FPG – poor sensitivity• HbA1c – reliability issues in the first year• OGTT – cumbersome, timing of OGTT• Gold standard• Reproducibility issues• Reversal – upto 20% over 5 years
• Novel approaches• Afternoon or late evening blood glucose• OGTT for those with HbA1c between 5.7 to 6.4 %
![Page 14: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/14.jpg)
How is it different?
![Page 15: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/15.jpg)
Effect of diabetes on transplant• Heart transplant – does not affect survival, increases hypertension,
renal failure, rejection and infection• Liver transplation – increases HCV infection and fibrosis, affects short
term survival but minimal effect on long term survival• Renal – decreases survival and increases rejection• PTDM better than pre existing DM
![Page 16: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/16.jpg)
Effect of diabetes on transplant
![Page 17: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/17.jpg)
Management• Goals not clearly established• Prevention • Treatment
![Page 18: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/18.jpg)
Risk factors
Sharif, Adnan; Cohney, Solomon (2015): Post-transplantation diabetes—state of the art. In The Lancet Diabetes & Endocrinology.
![Page 19: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/19.jpg)
In patient treatment considerations
![Page 20: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/20.jpg)
Renal impairment and diabetes drugs
![Page 21: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/21.jpg)
![Page 22: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/22.jpg)
OHAs – potential considerations
![Page 23: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/23.jpg)
CV risk mitigation• BP control• KDOQI - <140/80 mm Hg• KDIGO - <130 / 80 mm Hg• ACE inhibitor / ARB – first line, prefer ARB in hyperkalemia• Diuretics are second line• CCBs – drug interaction with immunosuppressants
• Dyslipidemia management• Statins – weaker evidence base• Sirolimus and everolimus – severe hypertriglyceridemia• Statins + fibrates / niacin – rhabdomyolisis / liver injury in patients taking CNI
![Page 24: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/24.jpg)
Others• Eye care and feet care same as routine diabetes• Annual influenza vaccine• 5 yearly Pneumococcal vaccine• Tacrolimus /sirolimus induced oligospermia / hypogonadism• Contraception / prepregnancy counseling
![Page 25: Post Transplant Diabetes Mellitus](https://reader036.vdocuments.mx/reader036/viewer/2022070523/58edb3881a28ab684e8b4685/html5/thumbnails/25.jpg)
Summary• PTDM prevalence depends on definition – substantial burden• Pitfalls in diagnosis – wait till at least 3 months after transplant• Preventive advice important, risk prediction algorithms not well
developed yet• ?tackle non traditional risk factors
• Metformin, Linagliptin and insulin • Drug interactions – increase toxicity / decrease efficacy of
immunosuppressive agents• Team work